Discovery of Mer kinase inhibitors by virtual screening using Structural Protein–Ligand Interaction Fingerprints

• Published in: Bioorganic & medicinal chemistry Vol. 23; no. 5; pp. 1096 - 1101
• Main Authors: Da, C., Stashko, M., Jayakody, C., Wang, X., Janzen, W., Frye, S., Kireev, D.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.03.2015
• Subjects: Acute lymphoblastic leukemia; Mer tyrosine kinase; Molecular Docking Simulation; Protein Kinase Inhibitors - chemistry; Protein Kinase Inhibitors - pharmacology; Quality Control; Receptor Protein-Tyrosine Kinases - antagonists & inhibitors; Structural Protein–Ligand Interaction Fingerprints; Virtual screening; ALL; Acute lymphoblastic leukemia; ECFP; Virtual screening; Structural Protein–Ligand Interaction Fingerprints; Mer; SPLIF; VS; Mer tyrosine kinase
• ISSN: 0968-0896; 1464-3391; 1464-3391
• DOI: 10.1016/j.bmc.2015.01.001

[Display omitted] Mer is a receptor tyrosine kinase implicated in acute lymphoblastic leukemia (ALL), the most common malignancy in children. The currently available data provide a rationale for development of Mer kinase inhibitors as cancer therapeutics that can target both cell autologous and immune-modulatory anti-tumor effects. We have previously reported several series of potent Mer inhibitors and the objective of the current report is to identify a chemically dissimilar back-up series that might circumvent potential, but currently unknown, flaws inherent to the lead series. To this end, we virtually screened a database of ∼3.8million commercially available compounds using high-throughput docking followed by a filter involving Structural Protein–Ligand Interaction Fingerprints (SPLIF). SPLIF permits a quantitative assessment of whether a docking pose interacts with the protein target similarly to an endogenous or known synthetic ligand, and therefore helps to improve both sensitivity and specificity with respect to the docking score alone. Of the total of 62 experimentally tested compounds, 15 demonstrated reliable dose-dependent responses in the Mer in vitro kinase activity assay with inhibitory potencies ranging from 0.46μM to 9.9μM.